Elevance Health (ELV) is a publicly traded Healthcare sector company. As of May 20, 2026, ELV trades at $394.13 with a market cap of $85.58B and a P/E ratio of 15.96. ELV moved -2.37% today. Year to date, ELV is +13.56%; over the trailing twelve months it is -0.38%. Its 52-week range spans $273.71 to $528.52. Analyst consensus is buy with an average price target of $387.47. Rallies surfaces ELV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Elevance Health Buy Rating Boosts Target to $498 on 14.5x 2028 Earnings: Analysts upgraded Elevance Health to Buy, lifting its price target to $498 from $363 based on a 14.5x multiple of projected 2028 earnings of $34.34 per share. Broader sector upgrades reflect confidence that medical cost inflation has peaked, positioning the company for margin improvement through disciplined pricing and improved underwriting.
| Metric | Value |
|---|---|
| Price | $394.13 |
| Market Cap | $85.58B |
| P/E Ratio | 15.96 |
| EPS | $25.28 |
| Dividend Yield | 1.72% |
| 52-Week High | $528.52 |
| 52-Week Low | $273.71 |
| Volume | 489.80K |
| Avg Volume | 0 |
| Revenue (TTM) | $199.13B |
| Net Income | $5.66B |
| Gross Margin | 89.36% |
16 analysts cover ELV: 0 strong buy, 11 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $387.47.